Cost-effectiveness analysis of COVID-19 booster doses and oral antivirals: Case studies in the Indo-Pacific
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0294091 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Gizem Mayis Bilgin und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australia. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Antiviral Agents, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Decision-makers in middle-income countries need evidence on the cost-effectiveness of COVID-19 booster doses and oral antivirals to appropriately prioritise these healthcare interventions.
Methods
We used a dynamic transmission model to assess the cost-effectiveness of COVID-19 booster doses and oral antivirals in Fiji, Indonesia, Papua New Guinea, and Timor-Leste. We conducted cost-effectiveness analysis from both healthcare and societal perspectives using data collated from publicly available sources. We developed an interactive R Shiny which allows the user to vary key model assumptions, such as the choice of discounting rate, and view how these assumptions affect model results.
Findings
Booster doses were cost saving and therefore cost-effective in all four middle-income settings from both healthcare and societal perspectives using 3% discounting. Providing oral antivirals was cost-effective from a healthcare perspective if procured at a low generic price (US$25) or middle-income reference price (US$250); however, their cost-effectiveness was strongly influenced by rates of wastage or misuse, and the ongoing costs of care for patients hospitalised with COVID-19. The cost or wastage of rapid antigen tests did not appear strongly influential over the cost-effectiveness of oral antivirals in any of the four study settings.
Conclusions
Our results support that COVID-19 booster programs are cost-effective in middle-income settings. Oral antivirals demonstrate the potential to be cost-effective if procured at or below a middle-income reference price of US$250 per schedule. Further research should quantify the rates of wastage or misuse of oral COVID-19 antivirals in middle-income settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australia.
- Faculty of Economics and Business, Universitas Indonesia, Jakarta, Indonesia.
ORCID-Profile: Gizem Mayis Bilgin
Zitieren
APA
Bilgin, G. M., Munira, S. L., Lokuge, K., & Glass, K. (2024). Cost-effectiveness analysis of COVID-19 booster doses and oral antivirals: Case studies in the Indo-Pacific. PLOS ONE. https://doi.org/10.1371/journal.pone.0294091
Vancouver
Bilgin GM, Munira SL, Lokuge K, Glass K. Cost-effectiveness analysis of COVID-19 booster doses and oral antivirals: Case studies in the Indo-Pacific. PLOS ONE. 2024. doi:10.1371/journal.pone.0294091
BibTeX
@article{Bilgin2024,
author = {Bilgin, Gizem Mayis and Munira, Syarifah Liza and Lokuge, Kamalini and Glass, Kathryn},
title = {Cost-effectiveness analysis of COVID-19 booster doses and oral antivirals: Case studies in the Indo-Pacific},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0294091}
}
EUVIMED